Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating.

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

Researchers have developed an AI system capable of predicting whether and why proteins form sticky clumps, a process ...

The United States recently charged two Chinese nationals for allegedly smuggling a “dangerous biological pathogen” into the ...

The South Dakota Department of Health announced Tuesday a Meade County resident developed a measles infection after traveling ...

This study presents compelling evidence that the denitrosylase SCoR2 regulates cardioprotective metabolic reprogramming in the heart following ischemia/reperfusion injury. The findings are supported ...

Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, United States ...

Delivering a presidential address to General Synod in 2021, Archbishop Stephen Cottrell reaffirmed the goal of the Church of England’s national vision and strategy. It was a strategy for growth, he ...